Skip to main content
Clinical Trials/JPRN-UMIN000044484
JPRN-UMIN000044484
Completed
未知

A study evaluating the antihyperglycemic effect of botanical ingredient-containing food. - A study evaluating the antihyperglycemic effect of botanical ingredient-containing food.

Suntory Global Innovation Center Ltd.0 sites60 target enrollmentJune 18, 2021
Conditionsot applicable

Overview

Phase
未知
Intervention
Not specified
Conditions
ot applicable
Sponsor
Suntory Global Innovation Center Ltd.
Enrollment
60
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 18, 2021
End Date
October 30, 2021
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Suntory Global Innovation Center Ltd.

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\) Systolic pressure \<90 mmHg (2\) Subjects who are pregnant or lactating. (3\) Subjects who donated over 200ml blood components or whole blood within the past 4 weeks prior to the current study. (4\) Male who donated over 400ml whole blood within the past 12 weeks. (5\) Female who donated over 400ml whole blood within the past 16 weeks. (6\) Male whose blood was collected more than 1200 mL within the last 12 months when the amount of blood sampling in the current study is added. (7\) Female whose blood was collected over 800 mL within the last 12 months when the amount of blood sampling in the current study is added. (8\) Subjects who are participating in other clinical studies, or who finished clinical study within the last 4 weeks. (9\)Subjects a) with disease on heart, liver, kidney or other organs complications. b) with a previous history of disease on circulatory organs. c) who are contracting diabetes. d) with test food allergy. e) whose fasting blood glucose is equivalent to or higher than 140 mg/dL by a finger stick blood test. (10\) Subjects who have severe allergic reaction to drug medicine and food. (11\) Subjects with a previous history of feeling sick after blood sampling. (12\) Subjects who have difficulty in blood sampling from peripheral vein. (13\) Subjects who drink over 60 g of alcohol per day on average. (14\) Subjects who have irregular eating patterns. (15\) Subjects who work irregular shifts or at midnight. (16\) Subjects whose BMI is less than 18\.5 or over 30\.0 kg/m2\. (17\) Subjects who are constantly taking certain drug medicine, or who are expecting taking it within the period of current study, or who have indispensable supplements, functional foods affecting the test results. (18\) Subjects who are contracting atopic dermatitis and/or allergy symptoms. (19\) Subjects who are judged as unsuitable for the study by the principal investigator for other reasons.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Evaluation of Anti hyperglycemic Effect of internal septum of Juglans regia in patients with diabetes mellitus type II: A Double blind Randomized Clinical TrialType 2 diabetes mellitus.Type 2 diabetes mellitus without complicationsE11.9
IRCT20201229049877N1Tehran University of Medical Sciences60
Not yet recruiting
Not Applicable
Study about hyperglycemia inhibiting effect after meal of Agave Syrup.Type 2 diabetes
JPRN-UMIN000017686Showa Women&#39;s University10
Active, not recruiting
Not Applicable
The effect of a ketone drink on blood glucose levels in people with type 2 diabetesType 2 diabetesNutritional, Metabolic, Endocrine
ISRCTN45497544niversity of Exeter15
Recruiting
Phase 4
A trial investigating the effect on blood glucose after the injection of fast-acting insulin aspart (Fiasp®) in comparison to insulin aspart (NovoRapid®) around exercise in participants with type 1 diabetesE10Type 1 diabetes mellitus
DRKS00015855Forschungseinheit für interdisziplinäre metabolische Medizin, Medizinische Universität Graz44
Active, not recruiting
Phase 1
A study that investigates the effects of fast-acting insulin (FIASP®) on blood sugars in comparison to a different fast-acting insulin (NovoRapid®) around exercise in participants with type 1 diabetesType 1 DiabetesMedDRA version: 20.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2019-001281-14-ATMedical University of Graz44